John Ely

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

No current examples available.

Conflicts of Interest

No current examples available.

Contradictions

No current examples available.

Deceptions

No current examples available.

Recent Articles

Zepbound Outperforms Wegovy: New Study Shows Tirzepatide's Superior Weight Loss Effectiveness in Head-to-Head Comparison

Zepbound Outperforms Wegovy: New Study Shows Tirzepatide's Superior Weight Loss Effectiveness in Head-to-Head Comparison

Broke On: Monday, 08 July 2024 Zepbound outperforms Wegovy in head-to-head weight loss study, offering a more effective option for significant weight loss according to a JAMA Internal Medicine publication. The study found obese and overweight adults taking tirzepatide, the generic name for Zepbound and Mounjaro, lost more weight and did so faster than those taking semaglutide, the generic name for Wegovy and Ozempic. This marks a significant milestone in the competition between Eli Lilly and Novo Nordisk as they vie for market dominance in the weight loss market.
New Antibiotic Discovery Promises to Combat Drug-Resistant Superbugs

New Antibiotic Discovery Promises to Combat Drug-Resistant Superbugs

Broke On: Wednesday, 03 January 2024 Scientists have discovered a new class of antibiotic that can kill drug-resistant superbugs, including CRAB (carbapenem-resistant Acinetobacter baumannii), which is at the top of WHO's list of priority pathogens. Zosurabalpin works by targeting the LPS transport system in Gram-negative bacteria like A. baumannii, inhibiting their growth and causing toxicity inside cells that leads to death.